Long-term impact of interferon beta-1b in patients with CIS: 8-Year follow-up of BENEFIT

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 85, Issue 11, 2014, Pages 1183-1189

  Edan, G ^a   Kappos, Ludwig ^b   Montalban X ^c   Polman, C H ^d   Freedman, M S ^e   Hartung, H P ^f   Miller, D ^g   Barkhof, F ^d   Herrmann, J ^h   Lanius, V ⁱ   Stemper, B ⁱ   Pohl, C ^i,j   Sandbrink, R ^f,i   Pleimes, D ^k  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^h PAREXEL INTERNATIONAL   (United States)

ⁱ BAYER PHARMA AG   (Germany)

^j UNIVERSITY HOSPITAL BONN   (Germany)

^k Bayer HealthCare Pharmaceuticals Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON BETA SERINE;

ADULT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890295844     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2013-306222     Document Type: Article

References (18)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-52.
2. Ebers GC, Reder AT, Traboulsee A, et al. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther 2009;31:1724-36.
3. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-97.
4. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97.
5. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9.
6. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
7. Hartung HP, Freedman MS, Polman CH, et al. Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology 2011;77:835-43.
8. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122( pt 5):871-82.
9. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47:129-39.
10. EuroQol group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
11. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131( pt 3):808-17.
12. Penner IK, Stemper B, Calabrese P, et al. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler 2012;18:1466-71.
13. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 2010;133 (Pt 7):1914-29.
14. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010;133(Pt 7):1900-13.
15. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66:678-84.
16. Kinkel RP, Dontchev M, Kollman C, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012;69:183-90.
17. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
18. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11.